Article

Daily Medication Pearl: Vraylar (Cariprazine)

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Medication Pearl of the Day: Vraylar (Cariprazine)

Indication: Vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults, for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Insight:

  • Dosing: Patients can take Vraylar at 1.5 mg to 6 mg daily.
  • Dosage forms: Capsules of Vraylar come in dosages of 1.5 mg, 3 mg, 4.5 mg, and 6 mg.
  • Adverse events (AEs): Most common AEs include extrapyramidal symptoms and akathisia, extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness.
  • Mechanism of action: The efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
  • Manufacturer: Forest Laboratories

Source:

vraylar_pi.pdf (allergan.com)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com